首页 爱美医疗(usFOLD)-基本信息

爱美医疗(usFOLD)-基本信息

日报更新时间:07-02 06:53

周报更新时间:01-16 11:49

行情信息

今开价:23.1

最高价:23.36

成交量:1.625776E8

昨收价:23.29

最低价:21.79

最新价:21.835

行情图标
概要信息

中文名称:爱美医疗


英文名称:Amicus Therapeutics


行业:医疗


简介:Amicus Therapeutics, Inc.是一家生物制药公司,专注于口服,小分子药物的发现,开发和商业化,这种小分子药物称为药理伴侣分子,一种新型的,最初在类的方法来治疗各种疾病,包括溶酶体贮积病和神经变性疾病


电话:1-609-6622000


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Amicus Therapeutics, Inc.是一家生物制药公司,主要从事罕见病治疗产品(孤儿药)的开发与商业化应用,其候选产品为一种小分子,可用来作为单一疗法,结合为法布瑞氏症之酵素替代疗法(ERT)。爱美医疗公司开发项目包括: 治疗溶酶体储积症(LSDs)的新一代ERTs(Enzyme Replacement Therapies,酶替代疗法),如:法布瑞氏症、庞贝氏症及第一型黏多糖症; 药物伴护蛋白migalastat HCl,作为一种单一疗法,该产品已完成两项法布瑞氏症之Phase III全球注册研究; ATB200,是一种重组人类酸性α葡萄糖苷酶,产品处于治疗庞贝氏症之临床前开发后期阶段; AT3375,治疗帕金森氏症。爱美医疗Amicus Therapeutics(FOLD)历史沿革: 2007年,Amicus Therapeutics, Inc.登陆纳斯达克; 2013年11月,爱美医疗收购竞争对手Callidus Biopharma; 2015年9月,Amicus Therapeutics以9.47亿美金收购Scioderm。

交易日期 交易人 职位 类型 交易份额 价格
2019-07-31 Crowley (John F) Chief Executive Officer Sell 20000 12.54
2019-07-31 Crowley (John F) Chief Executive Officer Buy 20000 3.82
2019-06-30 Crowley (John F) Chief Executive Officer Buy 20000 3.82
2019-06-30 Crowley (John F) Chief Executive Officer Sell 20000 12.47
2019-06-26 Love (Ted Wendell) Director Buy 6250 --
2019-06-26 McGlynn (Margaret G) Director Buy 6250 --
2019-06-26 Raab (Michael G) Director Buy 6250 --
2019-06-26 Sblendorio (Glenn P) Director Buy 6250 --
2019-06-26 Whitman (Burke W) Director Buy 16667 --
2019-06-26 Wheeler (Craig A) Director Buy 6250 --
2019-06-26 Bleil (Lynn Dorsey) Director Buy 6250 --
2019-06-26 Essner (Robert) Director Buy 6250 --
2019-06-16 Quimi (Daphne) Chief Financial Officer Sell 1046 11.35
2019-06-16 Barth (Jay Allan) Officer Sell 1846 11.35
2019-06-16 Crowley (John F) Chief Executive Officer Sell 205 11.35
2019-06-13 Rosenberg (Ellen S) Officer Sell 662 11.35
2019-06-13 Do (Hung Viet) Officer Sell 1446 11.35
2019-06-02 Crowley (John F) Chief Executive Officer Sell 20000 11.15
2019-06-02 Crowley (John F) Chief Executive Officer Buy 20000 3.82
2019-06-02 Raab (Michael G) Director Buy 5000 7.15
2019-06-02 Raab (Michael G) Director Sell 5000 11.16
2019-04-30 Crowley (John F) Chief Executive Officer Sell 20000 13.51
2019-04-30 Crowley (John F) Chief Executive Officer Buy 20000 3.82
2019-04-10 Quimi (Daphne) Chief Financial Officer Buy 12347 --
2019-04-10 Campbell (Bradley L) Chief Operating Officer Buy 30183 --

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
PGIM Investments LLC 4632383 1.82% -736884 -13.72% 2019-07-31
HHG PLC 11056142 4.35% -17442 -0.16% 2019-03-31
Marshall Wace North America LP 12860038 5.06% 7543754 141.90% 2019-03-31
Fidelity Management and Research Company 14939215 5.87% -2448714 -14.08% 2019-03-31
FMR Inc 15179860 5.97% -2763663 -15.40% 2019-03-31
BlackRock Inc 16774752 6.60% 252932 1.53% 2019-03-31
Vanguard Group Inc 19820543 7.79% 2648546 15.42% 2019-03-31
Redmile Group, LLC 19616062 7.71% 11292845 135.68% 2019-03-31
Perceptive Advisors LLC 21639486 8.51% 915062 4.42% 2019-03-31
BlackRock Fund Advisors 10346372 4.06% 89979 0.88% 2019-07-31
venBio Select Advisor LLC 9500000 3.74% -625000 -6.17% 2019-03-31
State Street Corporation 8663483 3.41% 108931 1.27% 2019-03-31
SSGA Funds Management Inc 5146153 2.02% 78478 1.55% 2019-07-31
Fidelity SelectCo, LLC 6291809 2.47% -93100 -1.46% 2019-07-31
Citadel Advisors Llc 6434414 2.53% 5562878 638.28% 2019-03-31
Janus Capital Management LLC 6638680 2.60% -153481 -2.26% 2019-07-31
Vanguard Investments Australia Ltd 6816785 2.67% 805 0.01% 2019-07-31
Palo Alto Investors, LLC 7619833 3.00% 218512 2.95% 2019-03-31
Wellington Management Company LLP 7713651 3.03% 141689 1.87% 2019-03-31
Jennison Associates LLC 8624937 3.39% -1199435 -12.21% 2019-03-31
Amvescap Plc. 5334031 2.10% -283991 -5.05% 2018-12-31
Fidelity Management & Research Company 5361386 2.11% -3315373 -38.21% 2019-06-30
Morgan Stanley - Brokerage Accounts 5351546 2.32% 836321 18.52% 2018-12-31
Deutsche Asset Management Investment GmbH 5405852 2.34% 4051835 299.25% 2019-05-31
Sectoral Asset Management Inc 4867290 2.56% 1173600 31.77% 2018-09-30
BlackRock Institutional Trust Company NA 5343239 2.82% 254930 5.01% 2018-06-30
Orbimed Advisors, LLC 7072500 3.74% -- -- 2018-06-30
T. Rowe Price Associates, Inc. 5915945 3.13% 966312 19.52% 2018-06-30
State Street Corp 7962456 -- -587121 -6.87% 2018-06-30
Morgan Stanley & Co Inc 4829156 -- 4157477 618.97% 2018-06-30
Franklin Advisers Inc 4003233 -- 268044 7.18% 2018-06-30
Invesco Advisers, Inc 4198661 -- 1064220 33.95% 2018-06-30
D. E. Shaw & Co LP 3725044 -- -694735 -15.72% 2018-06-30
Farallon Capital Management, L.L.C. 3655000 -- 174000 5.00% 2018-06-30
Prudential Investment Management Inc 10301723 -- 421313 4.26% 2017-12-31
Tourbillon Capital Partners LP 3288300 1.97% 250000 8.23% 2017-12-31
Wells Fargo Bank NA 2750228 1.46% 2055035 295.61% 2018-03-31
Point72 Asset Management, L.P. 2870100 1.72% 1130654 65.00% 2017-12-31
Fidelity Institutional Asset Management 3240716 1.96% -165719 -4.86% 2017-09-30
Eagle Asset Management, Inc. 2661511 1.60% -36991 -1.37% 2017-12-31
Morgan Stanley Investment Management Inc 4736692 2.85% -2463146 -34.21% 2017-12-29
Victory Capital Management Inc. 2493169 1.51% -1876410 -42.94% 2017-09-30
RS Investment Management Co. LLC 2761883 1.94% 411940 17.53% 2016-09-30
Artal Group S A 1900000 1.34% 650000 52.00% 2016-09-30
AllianceBernstein LP 1844529 1.30% -257713 -12.26% 2016-09-30
ING Investment Management LLC 1638471 1.15% -271725 -14.22% 2016-09-30
Entities affiliated with Redmile Group, LLC 8475274 3.00% 92210981 0.10% 1999-11-30
Entities affiliated with Perceptive Advisors LLC 14439444 3.00% 157101151 0.20% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Franklin Biotechnology Discovery Fund 1270000 0.50% -- -- 2019-06-30
Vanguard Total Stock Market Index Fund 6763605 2.66% 1113 0.02% 2019-06-30
Vanguard Small Cap Index 6283771 2.47% -163295 -2.53% 2019-06-30
iShares Russell 2000 ETF 5079701 1.99% 49937 0.99% 2019-07-30
SPDR 4955615 1.95% 77040 1.58% 2019-07-31
Janus Henderson Triton Fund 4190693 1.65% -- -- 2019-06-30
Vanguard Small Cap Growth Index Fund 3615189 1.42% -41784 -1.14% 2019-06-30
Vanguard Extended Market Index Fund 3399562 1.34% 70310 2.11% 2019-06-30
PGIM Jennison Health Sciences Fund 3136734 1.23% -- -- 2019-06-30
iShares Nasdaq Biotechnology ETF 2435602 0.96% 24263 1.01% 2019-07-30
iShares Russell 2000 Growth ETF 2125345 0.83% 30960 1.48% 2019-07-30
JNL/Invesco Small Cap Growth Fund 1385656 0.54% -15772 -1.13% 2019-03-31
Janus Henderson Global Life Sciences Fd 1499172 0.59% -11546 -0.76% 2019-06-30
Eventide Healthcare & Life Sciences Fund 1615000 0.63% 279000 20.88% 2019-03-31
Fidelity 1809781 0.71% -93100 -4.89% 2019-06-30
Carillon Eagle Small Cap Growth Fund 1859320 0.73% -- -- 2019-06-30
Victory RS Small Cap Growth Fund 2029995 0.80% 400810 24.60% 2019-06-30
Invesco Small Cap Growth Fund 2073367 0.81% -- -- 2019-06-30
Pictet-Biotech 1399057 0.55% -5778 -0.41% 2018-09-30
PGIM Jennison Small Company Fund 1862389 0.73% -- -- 2019-05-31
iShares US Small Cap ETF (CAD-Hedged) 3849281 1.67% -6462 -0.17% 2019-05-30
DWS Verm 2600000 1.13% 1950000 300.00% 2019-04-30
DWS Biotech 2802852 1.21% 2101835 299.83% 2019-04-30
Vanguard Small Cap Index Fund 5703861 2.47% 33411 0.59% 2019-04-30
Variopartner Sectoral Biotech Opps Fd 1629492 0.71% -290000 -15.11% 2019-01-31
Fidelity Advisor 1694970 0.89% -- -- 2018-12-31
Columbia Mid Cap Growth 1640895 0.87% 1640895 -- 2018-06-30
Worldwide Healthcare 1676083 0.89% -- -- 2018-07-31
Janus Global Life Sciences D 1996885 1.06% -164537 -7.61% 2018-06-30
Franklin Small Cap Growth A 1198900 0.63% -- -- 2018-07-31
T. Rowe Price New Horizons 1317446 0.70% 60075 4.78% 2018-06-30
iShares Russell 2000 Growth 1846053 0.86% -1780 -0.10% 2018-09-12
Vanguard Total Stock Mkt Idx 4698604 2.48% 5382 0.11% 2018-07-31
Janus Triton D 2964489 1.57% -- -- 2018-06-30
Prudential Jennison Health Sciences A 3136734 1.66% -- -- 2018-07-31
Prudential Jennison Small Company B 2771938 1.47% -48342 -1.71% 2018-07-31
Vanguard Small Cap Growth Index Inv 2709305 1.43% 41391 1.55% 2018-07-31
Vanguard Extended Market Idx Inv 2490084 1.32% 32000 1.30% 2018-07-31
T. Rowe Price Health Sciences 2014247 1.07% 239693 13.51% 2018-06-30
Eagle Small Cap Growth A 1859320 0.98% -- -- 2018-06-30
RS Small Cap Growth A 1836215 0.97% 389340 26.91% 2018-06-30
Invesco Small Cap Growth A 1640084 0.87% 224090 15.83% 2018-06-30
iShares Nasdaq Biotechnology 2137210 1.00% -4068 -0.19% 2018-09-12
Columbia Mid Cap Growth Z 1640895 0.87% -- -- 2018-07-31
Lord Abbett Developing Growth A 1138090 0.61% 52256 4.81% 2018-02-28
FIAM Small Company Pool 948324 0.57% 139251 17.21% 2017-09-30
Franklin Biotechnology Discovery A 933900 0.56% 197800 26.87% 2017-09-30
FIAM Small Cap Core Pool 921900 0.65% 14400 1.59% 2016-09-30
iShares US Pharmaceuticals 1358359 1.04% -- -- 2017-02-07
T. Rowe Price Health Sciences Fund 3177665 2.50% 31865 1.00% 2015-09-30
Fidelity® Magellan® Fund 2849153 2.30% -- -- 2015-09-30
Janus Global Life Sciences Fund 2462593 2.00% 619834 33.60% 2015-09-30
RS Small Cap Growth Fund 1894184 1.50% -90670 -4.60% 2015-09-30
iShares Russell 2000 (AU) 1838364 2.00% -2316 -0.10% 2015-11-19
Lord Abbett Developing Growth Fund 1758677 1.40% 1390177 377.20% 2015-09-30
Fidelity® Select Health Care Portfolio 1600000 1.30% -- -- 2015-09-30
Prudential Jennison Health Sciences 1332291 1.10% -- -- 2015-09-30
SPDR® S&P Biotech ETF 1303647 1.40% 8516 0.70% 2015-11-19
Goldman Sachs Small/Mid Cap Growth Fund 1119207 0.90% 35591 3.30% 2015-09-30
Fidelity® Select Biotechnology Portfolio 3392125 2.70% -- -- 2015-09-30

John Francis Crowley John Francis Crowley founded Orexigen Therapeutics, Inc. and Novazyme Pharmaceuticals, Inc. Presently, Mr. Crowley holds the position of Chairman & Chief Executive Officer at Amicus Therapeutics, Inc. Mr. Crowley is also on the board of 6 other companies. He previously occupied the position of Director-Business Strategy at Bristol-Myers Squibb Co., President & Chief Executive Officer at Orexigen Therapeutics, Inc., President & Chief Executive Officer for Novazyme Pharmaceuticals, Inc., Litigation Associate-Health Care Practice Group at Bingham Summers Welsh & Spilman, Senior Vice President at Genzyme Therapeutics Ltd. and National Chairman at Make-A-Wish Foundation of America. He received an undergraduate degree from Georgetown University, a graduate degree from the University of Notre Dame The Law School and an MBA from Harvard Business School.
Bradley Lewis Campbell Bradley Lewis Campbell is on the board of Progenics Pharmaceuticals, Inc., BioNJ, Inc., Amicus Therapeutics UK Ltd. and New Jersey Health Initiatives and President, Chief Operating Officer & Director at Amicus Therapeutics, Inc. He previously was Business Director-Cardiac Gene Therapy Programs at Genzyme Corp. and Director at National Tay-Sachs & Allied Diseases Association. Mr. Campbell received an undergraduate degree from Duke University and an MBA from Harvard Business School.
Bradley Lewis Campbell Bradley Lewis Campbell is on the board of Progenics Pharmaceuticals, Inc., BioNJ, Inc., Amicus Therapeutics UK Ltd. and New Jersey Health Initiatives and President, Chief Operating Officer & Director at Amicus Therapeutics, Inc. He previously was Business Director-Cardiac Gene Therapy Programs at Genzyme Corp. and Director at National Tay-Sachs & Allied Diseases Association. Mr. Campbell received an undergraduate degree from Duke University and an MBA from Harvard Business School.
Enrique Dilone Enrique Dilone is Senior Vice President-Technical Operations at Amicus Therapeutics, Inc. Dr. Dilone is also on the board of La Casa de Don Pedro, Inc. In the past Dr. Dilone occupied the position of Executive Director-Quality & Analytics at NovaDel Pharma, Inc. and Director-Analytical Operations at Eyetech Pharmaceuticals, Inc. Enrique Dilone received a doctorate and a graduate degree from Seton Hall University and an undergraduate degree from New York University.
Jeffrey P. Castelli Jeffrey P. Castelli is Chief Portfolio Officer & Head-Gene Therapy at Amicus Therapeutics, Inc. In the past he occupied the position of Business Development Analyst at Neose Pharmaceuticals, Inc. and Manager at Health Advances LLC. Dr. Castelli received an undergraduate degree from West Chester University of Pennsylvania and a doctorate from the University of Pennsylvania.
Jayne C. Gershkowitz Founder of BioNJ, Inc. and Professional Patient Advocates In Life Sciences, Jayne C. Gershkowitz is on the board of Professional Patient Advocates In Life Sciences and Chairman-Patient Advocacy Committee at BioNJ, Inc. and Chief Patient Advocate at Amicus Therapeutics, Inc. Ms. Gershkowitz received an undergraduate degree from S.I. Newhouse School of Public Communications.
Lynn Dorsey Bleil Lynn Dorsey Bleil is on the board of Stericycle, Inc. and 4 other companies. In the past Ms. Bleil held the position of Senior Partner at McKinsey & Co., Inc. She received an undergraduate degree from Princeton University and an MBA from Stanford Graduate School of Business.
Donald J. Hayden Currently, Michael G. Raab is President, Chief Executive Officer & Director at Ardelyx, Inc. Mr. Raab is also on the board of Amicus Therapeutics, Inc. and California Biomedical Innovation Alliance and Member of Biotechnology Innovation Organization. In his past career he occupied the position of Principal at Repligen Corp., Senior Vice President at Therapeutics, Inc., Principal at Bristol-Myers Squibb Co., Partner at NEA Management Co. LLC and Senior Vice President-Therapeutics & GM-Renagel at Genzyme Corp. He received an undergraduate degree from DePauw University.
Robert A. Essner Robert A. Essner is a businessperson who has been the head of 6 different companies and presently is Executive Chairman of Elucida Oncology, Inc. He is also on the board of 6 other companies. In the past Mr. Essner held the position of Chairman & Chief Executive Officer at Wyeth Pharmaceuticals, Inc., Chief Executive Officer at Fort Dodge Animal Health, Inc., President at Ayerst Laboratories, Inc., President-Consumer Healthcare Group at Sandoz Pharmaceuticals Corp., Senior Advisor at The Carlyle Group LP (Corporate Private Equity) and Chairman for Pharmaceutical Research & Manufacturers of America. Mr. Essner received a graduate degree from The University of Chicago and an undergraduate degree from Miami University.
Burke W. Whitman Burke W. Whitman is on the board of Omega Healthcare Investors, Inc., Amicus Therapeutics, Inc. and Marine Toys for Tots Foundation. Mr. Whitman previously held the position of President & Chief Financial Officer for Deerfield Healthcare Corp., President, Chief Executive Officer & Director at Health Management Associates, Inc., Chief Financial Officer & Executive Vice President of Triad Hospitals, Inc. and Investment Banker at Morgan Stanley & Co. LLC. Burke W. Whitman received an undergraduate degree from Dartmouth College, an MBA from Harvard Business School and a graduate degree from U.S. Army War College.
Margaret G. McGlynn Margaret G. McGlynn is Chairman at HCU Network America and on the board of 5 other companies. Ms. McGlynn previously occupied the position of President-Global Vaccines & Anti-Infectives at Merck & Co., Inc., President at US Department of Health & Human Services (DC) and President, Chief Executive Officer & Director at International AIDS Vaccine Initiative, Inc. Margaret G. McGlynn received an MBA and an undergraduate degree from State University of New York at Buffalo.
Ted W. Love Currently, Ted W. Love occupies the position of President, Chief Executive Officer & Director at Global Blood Therapeutics, Inc. Dr. Love is also on the board of Amicus Therapeutics, Inc., Predix Pharmaceuticals, Inc., Biotechnology Innovation Organization and Avillion LLP. In his past career Ted W. Love occupied the position of Senior Vice President-Development at Innoviva, Inc., Chairman, President & Chief Executive Officer of Nuvelo, Inc., Lead Independent Director at Humanigen, Inc., Executive VP & Head-Research & Development at Onyx Pharmaceuticals, Inc., Senior Vice President-Development at Theravance Biopharma US, Inc. and VP-Product Development & Regulatory Affairs at Genentech, Inc. Dr. Love received an undergraduate degree from Haverford College and a doctorate from Yale School of Medicine.
Glenn P. Sblendorio Glenn P. Sblendorio holds the position of President, Chief Executive Officer & Director at IVERIC bio, Inc. Mr. Sblendorio is also on the board of Amicus Therapeutics, Inc. and Intercept Pharmaceuticals, Inc. Mr. Sblendorio previously held the position of Chairman for NuLens Ltd., Chief Executive Officer & Managing Director at Mpm Capital Advisors LLC, President, CFO, Treasurer & Director at The Medicines Co., Chief Financial Officer at Millennium Venture Management LLC, Head-Finance & Controller at Amgen, Inc., Chief Financial Officer & Executive Vice President for Eyetech Pharmaceuticals, Inc., Chief Financial Officer of Hoffmann-La Roche, Inc., Chief Financial Officer & Vice President-Finance of Roche Molecular Systems, Inc. and Managing Director at Sony Interactive Entertainment, Inc. Glenn P. Sblendorio received an MBA from Fairleigh Dickinson University and an undergraduate degree from Pace University.
Craig A. Wheeler Craig A. Wheeler is a businessperson who has been the head of 5 different companies and currently holds the position of President, Chief Executive Officer & Director at Momenta Pharmaceuticals, Inc. He is also on the board of Amicus Therapeutics, Inc. and Member of Whitehead Institute for Biomedical Research. In the past he occupied the position of Senior Member-Health Care Practice at The Boston Consulting Group, Inc., Chairman at Avanir Pharmaceuticals, Inc., President at CHIRON Biopharmaceuticals, President of Chiron Corp. and Chairman of Association for Accessible Medicines. Mr. Wheeler received a graduate degree and an undergraduate degree from Cornell University and an MBA from The Wharton School of the University of Pennsylvania.
Michael G. Raab Presently, Michael G. Raab is President, Chief Executive Officer & Director at Ardelyx, Inc. Mr. Raab is also on the board of Amicus Therapeutics, Inc., Tempest Therapeutics, Inc. and California Biomedical Innovation Alliance and Member of Biotechnology Innovation Organization. In his past career Mr. Raab held the position of Principal at Repligen Corp., Senior Vice President of Therapeutics, Inc., Principal at Bristol-Myers Squibb Co., Partner at NEA Management Co. LLC and Senior Vice President-Therapeutics & GM-Renagel at Genzyme Corp. He received an undergraduate degree from DePauw University.
David Allsopp Mr. David Allsopp is a Senior Vice President-International at Amicus Therapeutics, Inc. He is on the Board of Directors at Swedish Orphan Biovitrum AB. He received his undergraduate degree from Coventry University.
Patrik S. Florencio Presently, Patrik S. Florencio occupies the position of Chief Compliance Officer & Chief Risk Officer at Amicus Therapeutics, Inc. In the past he was Chief Compliance Officer at Sandoz, Inc. and Chief Compliance Officer for NPS Pharmaceuticals, Inc. He received an undergraduate degree from McGill University.
Bradley Lewis Campbell Bradley Lewis Campbell is on the board of Progenics Pharmaceuticals, Inc., BioNJ, Inc., Amicus Therapeutics UK Ltd. and New Jersey Health Initiatives and President, Chief Operating Officer & Director at Amicus Therapeutics, Inc. He previously was Business Director-Cardiac Gene Therapy Programs at Genzyme Corp. and Director at National Tay-Sachs & Allied Diseases Association. Mr. Campbell received an undergraduate degree from Duke University and an MBA from Harvard Business School.
Sara Pellegrino Sara Pellegrino is Vice President-IR & Corporate Communications at Amicus Therapeutics, Inc.
Willem W. van Weperen Willem W. van Weperen is Regional Vice President at Amicus Therapeutics, Inc. In his past career he occupied the position of Chief Executive Officer at to-BBB technologies BV, Chief Executive Officer of to-BBB Holding BV, Principal at Naarden Agro Products BV, Clinical Researcher at Glaxo, Inc., General Manager for Genzyme Europe BV and Chief Commercial Officer for Prosensa Holding NV. He received a graduate degree from the University of Utrecht and an MBA from Nimbas Bradford School of Management.
Jay A. Barth Presently, Jay A. Barth is Chief Medical Officer at Amicus Therapeutics, Inc. He is also Member of American Gastroenterological Association, Member of The North American Society For Pediatric Gastroentrology and Member of American College of Gastroenterology. Jay A. Barth previously occupied the position of Senior Vice President-Clinical Development at PTC Therapeutics, Inc., Executive Director-Clinical Research at Merck & Co., Inc., VP-Clinical Research & Medical Affairs at ALTANA Pharma US, Inc. and Global Head-Gastroenterology Clinical Research at Eisai Medical Research, Inc. He received an undergraduate degree from Columbia University and a doctorate from Perelman School of Medicine.
Kurt J. W. Andrews Currently, Kurt J. W. Andrews is Senior Vice President-Human Resources at Amicus Therapeutics, Inc. and Chief Human Resources Officer for Immunomedics, Inc. In the past Mr. Andrews held the position of Vice President-Human Resources & Administration at PTC Therapeutics, Inc., Principal at Applera Corp., Vice President-Human Resources at Valeritas, Inc. and Director-Human Resources at V.I. Technologies, Inc. Mr. Andrews received a graduate degree and an undergraduate degree from the University of Illinois.
Lynn Dorsey Bleil Lynn Dorsey Bleil is on the board of Stericycle, Inc. and 4 other companies. In the past Ms. Bleil held the position of Senior Partner at McKinsey & Co., Inc. She received an undergraduate degree from Princeton University and an MBA from Stanford Graduate School of Business.
Daphne E. Quimi Currently, Daphne E. Quimi is Chief Financial Officer at Amicus Therapeutics, Inc. Ms. Quimi is also Member of Institute of Management Accountants, Inc. and Member of The American Institute of Certified Public Accountants. Ms. Quimi previously was Director-Consolidations & External Reporting at Bristol-Myers Squibb Co. She received an undergraduate degree from Monmouth University and an MBA from The Leonard N Stern School of Business.
Sara Pellegrino Sara Pellegrino is Vice President-IR & Corporate Communications at Amicus Therapeutics, Inc.
Jay A. Barth Presently, Jay A. Barth is Chief Medical Officer at Amicus Therapeutics, Inc. He is also Member of American Gastroenterological Association, Member of The North American Society For Pediatric Gastroentrology and Member of American College of Gastroenterology. Jay A. Barth previously occupied the position of Senior Vice President-Clinical Development at PTC Therapeutics, Inc., Executive Director-Clinical Research at Merck & Co., Inc., VP-Clinical Research & Medical Affairs at ALTANA Pharma US, Inc. and Global Head-Gastroenterology Clinical Research at Eisai Medical Research, Inc. He received an undergraduate degree from Columbia University and a doctorate from Perelman School of Medicine.
Hung Do Hung Do founded Callidus Biopharma, Inc. He is Chief Scientific Officer of Amicus Therapeutics, Inc. Dr. Do previously held the position of Director & Chief Scientific Officer at Callidus Biopharma, Inc., Principal at Novazyme Pharmaceuticals, Inc. and Project Leader at Genzyme Corp. Hung Do received a doctorate from Texas A&M University.
Ellen Stacy Rosenberg Ellen Stacy Rosenberg occupies the position of Secretary, Chief Legal Officer & General Counsel at Amicus Therapeutics, Inc. In her past career Ms. Rosenberg occupied the position of Associate General Counsel-Metabolic Endocrinology at EMD Serono, Inc., Secretary & Senior Vice President at Shire ViroPharma, Inc. and Secretary for NPS Pharmaceuticals, Inc. Ms. Rosenberg received an undergraduate degree from the University of Connecticut and a graduate degree from The University of Pennsylvania Law School.
Jay A. Barth Presently, Jay A. Barth is Chief Medical Officer at Amicus Therapeutics, Inc. He is also Member of American Gastroenterological Association, Member of The North American Society For Pediatric Gastroentrology and Member of American College of Gastroenterology. Jay A. Barth previously occupied the position of Senior Vice President-Clinical Development at PTC Therapeutics, Inc., Executive Director-Clinical Research at Merck & Co., Inc., VP-Clinical Research & Medical Affairs at ALTANA Pharma US, Inc. and Global Head-Gastroenterology Clinical Research at Eisai Medical Research, Inc. He received an undergraduate degree from Columbia University and a doctorate from Perelman School of Medicine.
Patrik S. Florencio Presently, Patrik S. Florencio occupies the position of Chief Compliance Officer & Chief Risk Officer at Amicus Therapeutics, Inc. In the past he was Chief Compliance Officer at Sandoz, Inc. and Chief Compliance Officer for NPS Pharmaceuticals, Inc. He received an undergraduate degree from McGill University.
Patrik S. Florencio Presently, Patrik S. Florencio occupies the position of Chief Compliance Officer & Chief Risk Officer at Amicus Therapeutics, Inc. In the past he was Chief Compliance Officer at Sandoz, Inc. and Chief Compliance Officer for NPS Pharmaceuticals, Inc. He received an undergraduate degree from McGill University.
Lynn Dorsey Bleil Lynn Dorsey Bleil is on the board of Stericycle, Inc. and 4 other companies. In the past Ms. Bleil held the position of Senior Partner at McKinsey & Co., Inc. She received an undergraduate degree from Princeton University and an MBA from Stanford Graduate School of Business.
Samantha Prout Samantha Prout occupies the position of Principal Accounting Officer & Global Controller at Amicus Therapeutics, Inc. In her past career Ms. Prout held the position of Director-Financial Reporting at NRG Energy, Inc. and Senior Manager-Audit at KPMG LLP. Ms. Prout received an undergraduate degree from Gettysburg College.
David M. Clark Currently, David M. Clark occupies the position of Chief People Officer at Amicus Therapeutics, Inc. Mr. Clark is also Chairman at Make-A-Wish Foundation of America and Member-Executive Board at Boy Scouts of America. In the past he was Vice President-Global Human Resources at Alibaba Group Holding Ltd. and Chief Learning Officer & SVP-Human Resources at American Express Co. He received an undergraduate degree from Indiana State University.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐